SureTrader
Home > Boards > US OTC > Medical - Equipment >

Titan Medical Inc. (TITXF)

TITXF RSS Feed
Add TITXF Price Alert      Hide Sticky   Hide Intro
Moderator: dndodd, glg20, buccaneer1961, cjrick01, investinthefuture, cptjsd
Search This Board:
Last Post: 8/24/2016 3:02:30 PM - Followers: 238 - Board type: Free - Posts Today: 90

 
 
Titan Medical Inc. is a Canadian public company, headquartered in Toronto, Ontario, that trades on the Toronto Stock Exchange (TMD) and the OTCQX in the United States (TITXF). Titan is developing the SPORT™ (Single Port Orifice Robotic Technology) Surgical System for use in minimally invasive surgery (“MIS”) that is expected to be commercially available in 2016. Titan’s robotic surgical system is being designed to expand robotic surgery into areas that are currently underserviced. This will allow surgeons to perform procedures within small to medium size surgical spaces such as general surgery and cholecystectomy. Currently, the most common medical procedures for which robotic systems are used are hysterectomies and prostatectomies. Titan plans to expand the scope and obtain approval for various surgical procedures as outlined in their Corporate Presentation.   http://www.titanmedicalinc.com/

The SPORT™ Surgical System includes the following:

* a single-port surgeon controlled robotic platform that includes a 3D vision system and interactive instruments for performing MIS procedures, and
* a surgeon workstation that provides the surgeon with an interface to the robotic platform   for controlling the interactive instruments and providing a 3D endoscopic view of inside a patient’s body during MIS procedures.

Titan is in the enginering verification phase of the SPORT™ Surgical System.

Global annual medical robotic revenues are currently approximately $4 billion and are expected to grow to $18 BILLION in 2018. Titan is planning to first commercialize the SPORT™ Surgical System in Europe followed by the United States, the world’s two largest markets for robotic surgery.  Currently, the robotic surgery marketplace is dominated by Intuitive Surgical.  This will likely change soon as their patents begin to expire and more competition is welcomed in an effort to lower costs and improve patient satisfaction.  

 Enter Titan Medical Inc. and their world-class team.




View the complete 
View the complete Titan Medical Investor Presentation 


VIDEOS  

TITAN MEDICAL 2015 AGM PRESENTATION  Partial Nephrectomy Dr. Dennis Fowler and the Future of Robotic Surgery
                                                                                        
 

           Bloom Burton & Co. names Titan Medical as a top 3 pick !              Dr. Valvo demonstrates SPORT™ at SAGES                                                                                                                                                                                                                                              


RECENT AND UPCOMING EVENTS

Titan Medical to Present at Bloom Burton Healthcare Investor Conference; Company to Report First Quarter 2016 Financial Results
http://www.titanmedicalinc.com/titan-medical-to-present-at-bloom-burton-healthcare-investor-conference-company-to-report-first-quarter-2016-financial-results

    Listen to The Titan Presentation at Bloom Burton Conference Here              Listen to the LIVE webcast here              
                                                                                                                                                 
  
Titan Medical Reports Strong Interest in SPORT™ Surgical System at SAGES 2016 Annual Meeting 
March 21st, 2016
 
 http://www.titanmedicalinc.com/titan-medical-reports-strong-interest-in-sport-surgical-system-at-sages-2016-annual-meeting    

INVESTOR RELATIONS

 
 

 

MICHAEL POLYVIOU - Senior Vice President

Michael Polyviou
mpolyviou@evcgroup.com
646-445-4800


Todd Kehrli
tkehrli@evcgroup.com
(310) 625-4462


 











 
 

SURGEON ADVISORY BOARD

Arnold Advincula, M.D.

Dr. Advincula is Vice-Chair of Women’s Health & Chief of Gynecology at the Sloane Hospital for Women, Columbia University Medical Center/New York Presbyterian Hospital. Formerly, he was Professor of Obstetrics and Gynecology, Director of the Minimally Invasive Surgery Division and Fellowship, and Director of the Endometriosis Center at the University of Michigan. More recently, he was Director of the Center for Specialized Gynecology and Director of the Education Institute at the Nicholson Center, an advanced medical and surgical simulation training facility at Florida Health. He is currently Vice President of the American Association of Gynecologic Laparoscopy and a Member-at-Large for the Society of Gynecologic Surgeons. He is a leader in minimally invasive surgical techniques and one of the world’s most experienced gynecologic robotic surgeons, who has published and taught extensively in the area of minimally invasive surgery, as well as developed surgical instruments that are in use worldwide.

Juliane Bingener-Casey, M.D

Dr. Juliane Bingener is Professor of Surgery, Mayo Clinic College of Medicine, and Vice Chair for Quality, Safety and Service in the Mayo Clinic Department of Surgery. She has a joint appointment in the Division of Gastroenterology and Hepatology, which supports her clinical interests in minimally invasive surgery, endoscopy, and gastrointestinal disease. Her research focuses on patient reported outcomes and novel technology in the diagnosis and treatment of these diseases. Dr. Bingener’s previous work included the development of a Natural Orifice Translumenal Endoscopic Surgery (NOTES) technique for using an omental patch to close perforated ulcers. Her ongoing interests focus on the development, study, and implementation of innovative endoscopic and laparoscopic approaches for gastrointestinal diseases.

Erik Dutson, M.D.

Dr. Dutson is Associate Professor of Surgery and Chief of the Section of Minimally Invasive and Bariatric Surgery at UCLA, and Executive Medical Director of UCLA’s Center for Advanced Surgical and Interventional Technology (CASIT), which is a multi-disciplinary laboratory with participation by the UCLA Schools of Medicine, Engineering, Computer Science and Applied Mathematics. He is a regular panel reviewer for NASA’s National Space Biomedical Research Institute/Human Research Program, as well as NIH’s section on Computer Modeling in Medicine. Formerly, he was a clinical and research fellow at the European Institute for Telesurgery at the University of Louis Pasteur in Strasbourg, France. While there, he helped develop and validate virtual and augmented-reality applications for surgery and participated in the training of approximately 8,000 surgeons from all over the world. He is a member of the SAGES, the SRS, the ASMBS, and a Fellow of the American College of Surgeons. He has authored multiple peer-reviewed scientific publications in surgical and engineering journals, and he helped develop CME accreditation for web-based surgical education tools. His clinical interests include laparoscopic and robotic bariatric surgery, and his research interests include the development of computer-assisted technology for surgical application.

Dennis Fowler, M.D., MPH

Dr. Fowler is the co-inventor of the single-incision Insertable Robotic Effector Platform (IREP) technology licensed from Columbia University for use in Titan Medical’s SPORT™ Surgical System. Dr. Fowler received his M.D. in 1973 from the University of Kansas School of Medicine, Kansas City. In 2008 he received his Master of Public Health from Columbia University, Mailman School of Public Health. Dr. Fowler is certified by the American Board of Surgery and is a member of numerous surgical societies. Formerly, he was the Gerald and Janet Carrus Professor of Surgical Science, Director of the Center for Innovation and Outcomes Research in the Department of Surgery, Columbia University College of Physicians and Surgeons, and V.P.-Medical Director of Perioperative Services at New York Presbyterian Hospital. As well he has a vast list of honours, committee positions, teaching responsibilities and publication credits.

Adrian Park, M.D. 

Dr. Park is Chairman of the Department of Surgery and Chair of the newly created Earl Simulation to Advance Innovation and Learning Center of Anne Arundel Health System in Annapolis, Maryland. Dr. Park has made major advancements in the improvement of laparoscopic procedures and the development of new medical devices for complex hernia repair, spleen and adrenal surgery. Dr. Park is a member of the American Surgical Association and is a Fellow of the Royal College of Surgeons of Canada, American College of Surgeons, and the College of Surgeons of Central Eastern and Southern Africa. Currently a member of the Board of Directors of the SAGES, he has also served as the Fellowship Council’s founding President and as its Board Chair. He is the editor-in-chief of Surgical Innovation, a bi-monthly peer-reviewed journal focused on minimally invasive surgeries. He is also the author of over 200 scholarly articles, the holder of 20 patents, and has been instrumental in the development and application of new technologies in endoscopic surgery.

Lee L Swanstrom, M.D.

Dr. Swanstrom heads the Division of GI and Minimally Invasive Surgery at the Oregon Clinic and is Director of the Providence Health System’s Complex GI and Foregut Surgery Postgraduate Fellowship Program. In addition, he is Clinical Professor in the Department of Surgery at OHSU, a Director of the American Board of Surgery, and Past President of both the Society of American Gastrointestinal Endoscopic Surgeons (SAGES) and the Fellowship Council (FC). Most recently, he became the Chief Innovations Officer and Director of the Innovations Fellowship at the Institutes des Hôpitalo Universitaires of the University of Strasbourg, France. He is the editor of Surgical Innovation and the author of over 300 scientific papers and 50 book chapters. This has resulted in 13 patents and a successful medical device startup company. He is and has been an investigator on numerous outcomes research studies for new procedures such as Natural Orifice Translumenal Endoscopic Surgery (NOTES) to determine their safety and efficacy for establishing new standards of care. He remains focused on developing innovative approaches to the minimally invasive treatment of foregut and other gastrointestinal disorders.

John Valvo, M.D. 

Dr. Valvo, a practicing surgeon, is the Executive Director of Robotic and Minimally Invasive Surgery at Rochester General Hospital in Rochester, New York, where he formerly was the Chief of Urology. Following a 20-year career performing open surgery, Dr. Valvo founded the robotic surgery program at Rochester General Hospital in early 2004, which currently ranks in the top two percent of robotic surgery volume in the United States. The program has trained over 30 robotic surgeons and enabled the completion of more than 7,000 robotic urology, gynecology, general and colorectal surgeries to date. Dr. Valvo has authored more than 100 scientific articles and helped start many robotic programs in the northeast. His focus on robotic surgery credentialing led to a notable published paper on policy guidelines for robotic surgery. He is a fellow of the American College of Surgeons and American Urological Association, and a member of the Society for Laparoscopic Surgeons.

Yanghee Woo, M.D. 

Dr. Yanghee Woo is an Assistant Professor of Surgery and the Director of the Global Excellence in Gastric Cancer Care at Columbia University Medical Center. She is an upper gastrointestinal surgeon with unique international training in minimally invasive/robotic surgery and expertise in the surgical treatment of tumors of the stomach, pancreas, small bowel, gallbladder and bile ducts. Dr. Woo is internationally recognized as a leader in robotic surgery for tumors of the stomach and pancreas, and gallbladder disease. She was the first surgeon in New York City to perform a single-site robotic cholecystectomy, multiport robotic gastric cancer operation with D2 lymphadenectomy, and robotic distal pancreatectomy for mucinous cystic lesion of the pancreas. She has numerous peer-reviewed publications, and she is invited to present at many lectures.


SECURED PATENTS

  Patent #                                                    Title of Invention
1 8,930,027   Force Feedback System
2 8,792,688   Methods, systems and devices for three dimensional input and control methods and systems based thereon
3 8,768,509   Snaking robotic arm with movable shapers
4 8,347,754   Multi articulating robotic instrument
5 8,332,072   Robotic hand controller
6 8,306,656   Method and system for performing medical procedure
7 8,224,485   Snaking robotic arm with movable shapers
8 5,853,394   Catheter
9 5,607,407   Catheter assembly
10 4,785,868   Medical needle and method for making
  PENDING PATENTS
  PUB. APP. NO.  Title
1 20140316435 METHODS, SYSTEMS AND DEVICES FOR THREE DIMENSIONAL INPUT AND CONTROL METHODS AND SYSTEMS BASED THEREON
2 20140276956 APPARATUS AND METHOD FOR CONTROLLING AN END-EFFECTOR ASSEMBLY
3 20140249546 APPARATUS AND METHOD FOR SUPPORTING A ROBOTIC ARM
4 20140230595 APPARATUS AND METHOD FOR CONTROLLING AN END-EFFECTOR ASSEMBLY
5 20130197697 FORCE FEEDBACK SYSTEM
6 20130197538 ROBOTIC HAND CONTROLLER
7 20120253513 SNAKING ROBOTIC ARM WITH MOVABLE SHAPERS
8 20100036393 METHODS, SYSTEMS AND DEVICES FOR THREEDIMENSIONAL INPUT, AND CONTROL METHODS AND SYSTEMS BASED THEREON

TITAN MEDICAL AND XIMEDICA

SPORT™ is being developed in colaboration with Ximedica inc.   SPORT™ with the team from Ximedica in New York for an investors demonstration.
http://www.ximedica.com/index.php/solutions/casestudy/titan-medical-sporttrade-surgical-system       Follow Ximedica Inc. on linkedIn by clicking here ⇒

BENEFITS  This is a cutting edge/cost-effective (mobile) robotic surgical system which is being developed, with input from the SAB along with an expert team at Ximedica, with an objective of delivering multiple benefits to patients, surgeons, hospitals and ambulatory surgery centers. These include:

For the Patient


A shorter hospital stay

Reduced pain, scarring, and risk of infection

Less blood loss

Quicker recovery

For the Surgeon


Enhanced functionality, dexterity, versatility, field of vision via 3D technology and precision.

Improved ergonomics which can potentially extend surgeons’ operating careers.

For the Hospital or Surgery Center


Decreased length of patient stay and reduced risk of infection improves patient throughput leading to improved return on assets.

Reduced risk of infection also contributes to improved margins on case rate procedures.

Increased patient satisfaction, which contributes to patient referrals and patient demand.
Increased physician satisfaction, which impacts physician demand for hospital usage in both robotic and non-robotic cases.

Lower cost / highly portable device (easily moved)

Improved Marketing with state of the art Robotic platform/technology available

 

Refer to sedar.com for specifics on warrants, milestone costs, and cash on hand.
  Investors can find more pictures and videos of SPORT™ at the Titan Medical Investors Group on Facebook by clicking here⇒ 
Follow Titan Medical Inc. on their LinkedIn site by clicking here⇒


 24 Month Stock Performance (TMD.TO and TITXF)

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
TITXF
Current Price
Volume:
Bid Ask Day's Range
SureTrader
PostSubject
#40949  Sticky Note Titan Medical Gurufocus correct link nla 07/19/16 11:52:04 AM
#35212  Sticky Note Titan Medical Inc. Announces Closing of Public Offering jhersh 03/31/16 09:40:18 AM
#34285  Sticky Note Titan Medical Facebook Group https://www.facebook.com/groups/TitanMedical.info/ SurgicalTechnologist 03/19/16 10:14:24 AM
#24852  Sticky Note The AGM is *finally* up: https://m.youtube.com/watch?v=MPh-LW11Vhk investinthefuture 08/20/15 05:04:58 PM
#17239  Sticky Note Here's a link to them: http://www.titanmedicalinc.com/wp-content/uploads/2014/ CUIN2 11/17/14 11:48:50 PM
#42998   Not a clue what he is thinking, but Hypocrates 08/24/16 03:39:32 PM
#42997   oh yes, for sure they are in the Geo2014 08/24/16 03:02:30 PM
#42995   Hard to say. I was the one who scalpel 08/24/16 02:48:23 PM
#42994   I'm not sure on the timeline, but JH Flenderson 08/24/16 02:40:08 PM
#42992   I simply cannot fathom the investment a lot DRG1025 08/24/16 02:31:23 PM
#42991   700k ? I even find that hard to belive. posilock 08/24/16 02:26:18 PM
#42990   Reply to my email. Not pumping juzt trying posilock 08/24/16 02:21:50 PM
#42989   When Hargrove was voted out as chair, it CUIN2 08/24/16 02:14:10 PM
#42987   Any thought on the logic behind why the JUrology 08/24/16 01:53:30 PM
#42986   I am repeatedly amazed watching the market makers scalpel 08/24/16 01:49:05 PM
#42984   That maybe true, but to assume that market scalpel 08/24/16 01:43:49 PM
#42983   Don't listen to people who claim inside info. El Guapo Roboto 08/24/16 01:32:44 PM
#42981   Yes, we should take the same approach to RockoTaco 08/24/16 01:31:15 PM
#42980   I think it's a very real possibility that Fitzy93 08/24/16 01:18:12 PM
#42979   I cant believe Im even asking this, but Geo2014 08/24/16 12:46:08 PM
#42978   A (simple) formal description from Investopedia... The most common Geo2014 08/24/16 12:35:33 PM
#42976   They dont have an inside track on info. Geo2014 08/24/16 12:29:26 PM
#42975   Mine is too. Im more concerned about Geo2014 08/24/16 12:24:41 PM
#42974   Agree with the FDA approval. BIGKAHUNA57 08/24/16 12:22:27 PM
#42972   i wish i could afford 700k shares. glg20 08/24/16 12:16:48 PM
#42971   Do what you have to do. You Geo2014 08/24/16 12:16:14 PM
#42970   Question to the board about Market Makers. I've DRG1025 08/24/16 12:13:31 PM
#42968   I bought Titan because some guy at work measles 08/24/16 12:12:58 PM
#42967   Most financial advisors would advise to stay away Geo2014 08/24/16 12:12:34 PM
#42965   My opinion is that FDA and CE approval Bristol19 08/24/16 12:01:56 PM
#42964   Focus on Titan reaching design freeze milestone before longtermgems 08/24/16 11:59:45 AM
#42963   And possilock... no disrespect, but you just admitted Noemotionseller 08/24/16 11:43:11 AM
#42962   Why do you ask? If you know something, Bristol19 08/24/16 11:41:41 AM
#42961   What would everyone's reaction be to John Hargrove Fitzy93 08/24/16 11:39:38 AM
#42959   EXACTLY... I have never heard of a financial Noemotionseller 08/24/16 11:31:19 AM
#42955   Please people email me at posilock@mail.com. not gmail.. posilock 08/24/16 11:02:28 AM
#42953   CHecked out Titan's Linkedin page today and found Hypocrates 08/24/16 10:49:31 AM
#42949   He didn't tell me to sell. He just DRG1025 08/24/16 10:30:08 AM
#42946   I can tell you from personal experience that flybabyfly 08/24/16 10:12:06 AM
#42942   Also, what financial advisor would suggest investing in bobbysixty 08/24/16 09:59:31 AM
#42939   Do what lets you sleep at night. dndodd 08/24/16 09:43:55 AM
#42937   At this stage of the game I have DRG1025 08/24/16 09:29:59 AM
#42933   Because gmail divulges my personel info please send posilock 08/24/16 08:26:08 AM
#42931   It's interesting how silent verb and jnj are RockoTaco 08/24/16 07:59:17 AM
#42930   It's not worth it, amazing the lack of RockoTaco 08/24/16 07:56:09 AM
#42928   Email me at posilock@gmail.com posilock 08/24/16 07:49:06 AM
#42924   Not allowed to say... you will all find posilock 08/24/16 07:36:51 AM
#42921   What do you know behind the scenes, Posi? JMAC13 08/24/16 07:25:45 AM
#42920   L9l.. sure whatever you say.. posilock 08/24/16 06:59:22 AM
#42919   You agree? CUIN2 08/24/16 06:34:24 AM
#42918   Good for you... posilock 08/24/16 06:33:12 AM
#42917   How would any of us know what's going CUIN2 08/24/16 06:32:23 AM
#42916   I know whats going on behind the scenes, posilock 08/24/16 06:31:09 AM
#42915   I will not buy shares and haven't bought CUIN2 08/24/16 06:30:52 AM
#42914   Posilock - for your own good, think about CUIN2 08/24/16 06:28:43 AM
PostSubject